Study confirms efficacy of Infiltrator catheter:
This article was originally published in Clinica
Executive Summary
A trial of Interventional Technologies' Infiltrator drug delivery catheter has demonstrated the safety and feasibility of using the device to deliver dilute ethanol in patients with in-stent restenosis. The Beaumont Alcohol Restenosis Study (BARS), which is assessing the procedure as a treatment for preventing in-stent restenosis, evaluated 24 patients with clinical evidence of ischaemia and diffuse in-stent restenosis. The patients received 15% ethanol delivered via the Infiltrator catheter. Procedural success was 100%, according to the San Diego, California company, with no major adverse in-hospital cardiac events. The study will now assess a further 25 patients who will receive 30% ethanol.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.